Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism.

Yu Bai <a class=“affiliation-link” title=“Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, P. R. China.” href=“https://pubmed.ncbi.nlm.nih.gov/38894572#full-view-affiliation-1" …